State of lipid metabolism in patients receiving androgen replacement therapy

Abstract

Objective. To assess the state of lipid metabolism indicators and predict cardiovascular risk in patients with secondary (acquired) hypogonadism on the background of androgen replacement therapy. Testosterone replacement therapy is often used in modern medicine for diagnosed androgen deficiency in patients of any age group. There are quite a lot of publications devoted to diagnosis and treatment, but the effectiveness and safety of any therapy is determined by several factors, of which two were considered in the presented study – dose-dependent effect and compliance.

Material and methods. Sixty two patients aged 30 to 52 years with androgen deficiency and a low risk of developing cardiovascular diseases were examined according to the Princeton Consensus criteria. Patients were divided into groups depending on the severity of androgen deficiency and the duration of therapy. Complaints, objective status, muscle strength, daily blood pressure and heart rate monitoring data, lipidogram and sex hormone indicators were evaluated.

Results. The obtained data suggest that androgen replacement therapy in doses that lead to an increase in the level of testosterone in the blood above the upper limit of reference values had a negative impact on the lipid spectrum and increased cardiovascular risk for this group of patients.

Conclusions. The analyzed approach to therapy of androgen deficiency should provide an individual adjustment of dosage on the background of determining the target blood testosterone level.

Keywords

Androgen deficiency / hormone replacement therapy / lipid metabolism disorders

References

[1] Vertkin A.L., Аrinina E.N., Morgunov L.Yu. etc. The prevalence of age-related hypogonadism in men with with somatic pathology. Human Health as the basis of national security: materials of the Siberian Congress. Krasnoyarsk 2006: 298–299 (in Russian).

[2] Верткин А.Л., Аринина Е.Н., Моргунов Л.Ю. и др. Распространенность возрастного гипогонадизма у мужчин с соматической патологией. Здоровье человека как основа национальной безопасности: материалы Сибирского конгресса. Красноярск 2006; 298–299.

[3] Lunenfeld B., Mskhalaya G., Zitzmann M., Arver S., Kalinchenko S., Tishova Y. et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 2015; 18 (1): 5–15. DOI: 10.3109/13685538.2015.1004049

[4] Lunenfeld B., Mskhalaya G., Zitz- mann M., Arver S., Kalinchenko S., Tishova Y. et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 2015; 18 (1): 5–15. DOI: 10.3109/13685538.2015.1004049.

[5] Pashkova E.Yu., Rozhdestvenskaya O.A. Age-related androgen deficiency in men: etiology, clinic, diagnosis, treatment. Andrology and genital surgery 2015; 1: 95–101. DOI: 10.17650/ 2070-9781-2015-1-95-101 (in Russian).

[6] Пашкова Е.Ю., Рождественская О.А. Возрастной андрогенный дефицит у мужчин: этиология, клиника, диагностика, лечение. Андрология и генитальная хирургия 2015; 1: 95–101. DOI: 10.17650/2070-9781-2015-1-95-101

[7] Grossman H., Fabre B., Lopez M. et al. Complex relationship between sex hormones, insulin resistance and leptin in men with and without prostatic disease. Aging Male 2015; 19 (1): 40–45. DOI: 10.3109/13685538. 2015.1100600. PMID: 26526283

[8] Grossman H., Fabre B., Lopez M. et al. Complex relationship between sex hormones, insulin resistance and leptin in men with and without prostatic disease. Aging Male 2015; 19 (1): 40–45. DOI: 10.3109/13685538.2015.1100600. PMID: 26526283

[9] Ametov A. S., Pashkova E. Yu. Evolution of testosterone replacement therapy. New forms – new features. Endocrinology. News. Opinions. Training 2017; 2: 55–65. DOI: 10.24411/2304-9529-2017-00006 (in Russian).

[10] Аметов А.С., Пашкова Е.Ю. Эволюция тестостеронзаместительной терапии. Новые формы – новые возможности. Эндокринология. Новости. Мнения. Обучение 2017; 2: 55–65. DOI: 10.24411/2304-9529-2017-00006

[11] Soisson V., Brailly T.S., Empana J.P., Feart C., Ryan J. et al. Low plasma testosterone and elevated carotid intima-media thickness: importance of low-grade inflammation in elderly men. Atherosclerosis 2012; 223: 244–249.

[12] Muller M., Van Der Schouw Y.T., Thijssen J.H., Grobbee D.E. Endogenous sex hormones and cardiovascular disease in men. J Clin Endocrinol Metab 2003; 88: 5076–5086.

RIGHTS & PERMISSIONS

Popov P.S., Kournikova I.A., Torshin V.I., Malyutina N.N.